Valeant Pharmaceuticals International Inc. (NYSE:VRX) was down 1.2% during mid-day trading on Monday . The stock traded as low as $28.03 and last traded at $28.76, with a volume of 19,157,500 shares traded. The stock had previously closed at $29.12.

Several equities research analysts have recently issued reports on VRX shares. Mizuho raised shares of Valeant Pharmaceuticals International from an “underperform” rating to a “neutral” rating and set a $25.00 price objective for the company in a research report on Thursday, August 11th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $33.00 price target (down from $58.00) on shares of Valeant Pharmaceuticals International in a research note on Friday, June 3rd. Rodman & Renshaw reiterated a “buy” rating and set a $90.00 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. TD Securities reiterated a “hold” rating and set a $38.00 price target on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 17th. Finally, Wells Fargo & Co. reiterated an “underperform” rating and set a $19.50 price target on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Six equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $60.32.

The company has a 50-day moving average of $26.00 and a 200 day moving average of $34.07. The company’s market capitalization is $10.00 billion.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.47 billion. During the same period last year, the business posted $2.14 EPS. The company’s quarterly revenue was down 11.4% on a year-over-year basis. On average, equities research analysts expect that Valeant Pharmaceuticals International Inc. will post $6.54 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, CEO Joseph C. Papa acquired 202,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Friday, June 10th. The stock was bought at an average price of $24.48 per share, for a total transaction of $4,944,960.00. Following the transaction, the chief executive officer now owns 2,442,199 shares in the company, valued at approximately $59,785,031.52. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Argeris N. Karabelas acquired 4,000 shares of Valeant Pharmaceuticals International stock in a transaction dated Thursday, August 11th. The shares were acquired at an average price of $24.65 per share, with a total value of $98,600.00. Following the transaction, the director now owns 20,726 shares in the company, valued at approximately $510,895.90. The disclosure for this purchase can be found here.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.